These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15848606)

  • 1. Iron deficiency--an underrecognized problem in nonanemic and erythrocytic kidney transplant recipients: risks and effects of ACEI and of iron treatment.
    Jimeno L; Rodado R; Campos M; Lanuza M
    Transplant Proc; 2005 Mar; 37(2):1007-8. PubMed ID: 15848606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.
    Jimeno L; Rodado R; Barrios Y; Campos M; Llorente S; Nicolas F; Minguela A
    Transplant Proc; 2005 Mar; 37(2):1012-3. PubMed ID: 15848608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramipril in post-renal transplant erythrocytosis.
    Esposito R; Giammarino A; De Blasio A; Martinelli V; Cirillo F; Scopacasa F; Federico S; Russo D
    J Nephrol; 2007; 20(1):57-62. PubMed ID: 17347974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis.
    Marubayashi S; Yamamoto H; Shibata S; Fudaba Y; Miyata Y; Fukuma K; Okada K; Hinoi T; Ikeda M; Maeda T; Oshiro Y; Dohi K
    Hiroshima J Med Sci; 1998 Sep; 47(3):121-4. PubMed ID: 9810784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study.
    Kessler M; Hestin D; Mayeux D; Mertes PM; Renoult E
    Clin Nephrol; 1996 Feb; 45(2):83-9. PubMed ID: 8846535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis after kidney transplantation: the role of erythropoietin, burst promoting activity and early erythroid progenitor cells.
    Lezaic V; Biljanovic-Paunovic L; Pavlovic-Kentera V; Djukanovic L
    Eur J Med Res; 2001 Jan; 6(1):27-32. PubMed ID: 11313188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation.
    Ok E; Akçiçek F; Töz H; Kürşat S; Töbü M; Başçi A; Mees EJ
    Transplantation; 1995 Jun; 59(11):1623-6. PubMed ID: 7778179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients.
    Kedzierska K; Kabat-Koperska J; Safranow K; Domański M; Gołembiewska E; Bober J; Bohatyrewicz R; Ciechanowski K
    Clin Transplant; 2008; 22(2):156-61. PubMed ID: 18339134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
    Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
    Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up.
    Torregrosa JV; Campistol JM; Montesinos M; Rogada AG; Oppenheimer F; Andreu J
    Transplantation; 1994 Aug; 58(3):311-4. PubMed ID: 8053053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of posttransplant erythrocytosis with enalapril.
    Rell K; Koziak K; Jarzyo I; Lao M; Gaciong Z
    Transplantation; 1994 Apr; 57(7):1059-63. PubMed ID: 8165703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incidence and management of anemia in renal transplantation: an observational-French study].
    Choukroun G; Deray G; Glotz D; Lebranchu Y; Dussol B; Bourbigot B; Lefrançois N; Cassuto-Viguier E; Toupance O; Hacen C; Lang P; Mazouz H; Martinez F
    Nephrol Ther; 2008 Dec; 4(7):575-83. PubMed ID: 18672417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of contributing factors of post transplant erythrocytosis in renal transplant patients.
    Ahmed S; Ahmed E; Naqvi R; Qureshi S
    J Pak Med Assoc; 2012 Dec; 62(12):1326-9. PubMed ID: 23866484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia.
    Basri N; Gendo MZ; Haider R; Abdullah KA; Hassan A; Shaheen FA
    Exp Clin Transplant; 2007 Jun; 5(1):607-9. PubMed ID: 17617052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients.
    Satoh S; Kaneko T; Seino K; Abe T; Omori S; Sugimura J; Fujioka T; Kubo T
    Nihon Jinzo Gakkai Shi; 1995 Jun; 37(6):343-7. PubMed ID: 7666600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors after renal transplantation.
    Bravo P; Felgueiras J; Santos C; Oliveira C; Ponce P
    Transplant Proc; 2008 Apr; 40(3):740-2. PubMed ID: 18455003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
    Ersoy A; Kahvecioglu S; Ersoy C; Cift A; Dilek K
    Transplant Proc; 2005 Jun; 37(5):2148-50. PubMed ID: 15964363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial.
    Halimi JM; Giraudeau B; Buchler M; Al-Najjar A; Etienne I; Laouad I; Bruyère F; Lebranchu Y
    Clin Transplant; 2007; 21(2):277-84. PubMed ID: 17425758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production?
    Gleiter CH
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):489-92. PubMed ID: 8937931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.